1
|
|
2
|
Seo JA, Im Y, Han SH, Lee CW, Lee JY. Unconventional Molecular Design Approach of High-Efficiency Deep Blue Thermally Activated Delayed Fluorescent Emitters Using Indolocarbazole as an Acceptor. ACS Appl Mater Interfaces 2017; 9:37864-37872. [PMID: 28980471 DOI: 10.1021/acsami.7b09351] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Unconventional blue thermally activated delayed fluorescent emitters having electron-donating type indolocarbazole as an acceptor were developed by attaching carbazolylcarbazole or acridine donors to the indolocarbazole acceptor. Three compounds were derived from the indolocarbazole acceptor. The indolocarbazole-acridine combined products showed efficient delayed fluorescent behavior and a high quantum efficiency of 19.5% with a color coordinate of (0.15, 0.16) when they were evaluated as thermally activated delayed fluorescent emitters in deep blue fluorescent devices. This is the first demonstration of the use of electron-donating carbazole-derived moieties as efficient acceptor units of blue thermally activated delayed fluorescent emitters.
Collapse
Affiliation(s)
- Jeong-A Seo
- School of Chemical Engineering, Sungkyunkwan University , 2066 Seobu-ro, Jangan-gu, Suwon, Gyeonggi 440-746, Korea
| | - Yirang Im
- School of Chemical Engineering, Sungkyunkwan University , 2066 Seobu-ro, Jangan-gu, Suwon, Gyeonggi 440-746, Korea
| | - Si Hyun Han
- School of Chemical Engineering, Sungkyunkwan University , 2066 Seobu-ro, Jangan-gu, Suwon, Gyeonggi 440-746, Korea
| | - Chil Won Lee
- Department of Chemistry, Dankook University , Cheonan, Chungcheongnam-do 31116, Korea
| | - Jun Yeob Lee
- School of Chemical Engineering, Sungkyunkwan University , 2066 Seobu-ro, Jangan-gu, Suwon, Gyeonggi 440-746, Korea
| |
Collapse
|
3
|
Lee DR, Kim BS, Lee CW, Im Y, Yook KS, Hwang SH, Lee JY. Above 30% external quantum efficiency in green delayed fluorescent organic light-emitting diodes. ACS Appl Mater Interfaces 2015; 7:9625-9629. [PMID: 25924007 DOI: 10.1021/acsami.5b01220] [Citation(s) in RCA: 58] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Highly efficient green thermally activated delayed fluorescent organic light-emitting diodes with an external quantum efficiency of 31.2% were investigated by using 3-(3-(carbazole-9-yl)phenyl) pyrido[3',2':4,5]furo[2,3-b]pyridine (3CzPFP) derived from carbazole and pyrido[3',2':4,5]furo[2,3-b]pyridine. The host material showed well-matched photoluminescence emission with absorption of the green dopant material, (4s,6s)-2,4,5,6-tetra(9H-carbazol-9-yl)isophthalonitrile (4CzIPN) and harvested all excitons of 4CzIPN. The 3CzPFP:4CzIPN film exhibited high photoluminescence quantum yield of 100%, and the green delayed fluorescence device employing the 3CzPFP host showed high maximum quantum efficiency of 31.2 ± 0.5% at 1% doping after optimization of the device structure.
Collapse
Affiliation(s)
- Dong Ryun Lee
- †Department of Polymer Science and Engineering, Dankook University, Gyeonggi-do 448-701, Korea
| | - Bo Seong Kim
- †Department of Polymer Science and Engineering, Dankook University, Gyeonggi-do 448-701, Korea
| | - Chil Won Lee
- †Department of Polymer Science and Engineering, Dankook University, Gyeonggi-do 448-701, Korea
| | - Yirang Im
- ‡School of Chemical Engineering, Sungkyunkwan University 2066, Seobu-ro, Jangan-gu, Suwon, Gyeonggi 440-746, Korea
| | - Kyoung Soo Yook
- ‡School of Chemical Engineering, Sungkyunkwan University 2066, Seobu-ro, Jangan-gu, Suwon, Gyeonggi 440-746, Korea
| | - Seok-Ho Hwang
- †Department of Polymer Science and Engineering, Dankook University, Gyeonggi-do 448-701, Korea
| | - Jun Yeob Lee
- ‡School of Chemical Engineering, Sungkyunkwan University 2066, Seobu-ro, Jangan-gu, Suwon, Gyeonggi 440-746, Korea
| |
Collapse
|
4
|
Lee CW, Im Y, Seo JA, Lee JY. Carboline derivatives with an ortho-linked terphenyl core for high quantum efficiency in blue phosphorescent organic light-emitting diodes. Chem Commun (Camb) 2013; 49:9860-2. [DOI: 10.1039/c3cc44944k] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
|
5
|
Im Y, Lee JY. Effect of the position of nitrogen in pyridoindole on photophysical properties and device performances of α-, β-, γ-carboline based high triplet energy host materials for deep blue devices. Chem Commun (Camb) 2013; 49:5948-50. [DOI: 10.1039/c3cc42131g] [Citation(s) in RCA: 72] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
6
|
Abstract
A white light-emitting diode was fabricated by preparing multilayer emitting films with an inserted buffer layer. The device structures are ITO/PEDOT:PSS/Emissive layer/LiF/Al. The emissive layer comprises a yellow-emitting layer of Poly[9,9-dioctylfluorenyl-2,7-diyl]-co-1,4-benzo-(2,1,3)-thiadiazole (F8BT), a blue-emitting layer of Poly[9,9-di-(2'-ethylhexyl)fluorenyl-2,7-diyl] (BEHF) and PEDOT:PSS as a buffer layer between the emission layers. The solution processed multi-layer polymer light-emitting diodes (PLED) were prepared by introduction of a water-soluble buffer layer between organic solvent soluble layers. We present white organic light-emitting diodes (WOLEDs) that has bilayer emission zones. This device exhibits a brightness of 280 cd/m2 and emission efficiency of 1.18 cd/A at 12.6 V. The device with a doped PEDOT:PSS layer and a thicker blue-emission layer exhibits CIE color coordinates of (0.30, 0.34), which is close to the white coordinates of (0.33, 0.33) used by the standard CIE color coordinates.
Collapse
Affiliation(s)
- Sungkoo Lee
- Green Chemistry and Engineering Department, Korea Institute of Industrial Technology (KITECH), Cheonan-Si, Chungnam 331-825, Republic of Korea
| | | | | | | |
Collapse
|
7
|
Jung HA, Lee J, Ahn HK, Park SH, Park YH, Im Y. Fluoropyrimidine/platinum-based first-line chemotherapy in metastatic esophageal squamous cell carcinoma: Prognostic factor analysis in 239 patients. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4088] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
8
|
Ahn HK, Lee S, Sohn JH, Park S, Ham YH, Seo JJ, Cho EY, Nam DH, Lee JI, Choi DH, Park W, Huh SJ, Park YH, Ahn JS, Im Y. Prognostic index for patients with brain metastases from breast cancer: A validation and refinement of the breast-specific graded prognostic assessment (GPA) index. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.1097] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
9
|
Park S, Ahn HK, Lim T, Park YH, Ahn JS, Im Y. CA 15-3 elevations according to breast cancer subtypes at initial diagnosis of metastatic breast cancer (MBC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e11109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
10
|
Ellis PA, Barrios CH, Im Y, Patre M, Branle F, Perez EA. MARIANNE: A phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.tps102] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
11
|
Lee S, Park YH, Cho EY, Ham YH, Seo JJ, Ahn JS, Im Y. Prognostic impact on FOXP3 expression in triple-negative breast cancer (TNBC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.1089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
12
|
Rhee J, Han S, Cha Y, Kim H, Oh D, Im S, Ro J, Im Y, Bang Y, Kim T. Serum-transforming growth factor-α (TGF-α) and response to lapatinib plus capecitabine in HER2-positive (HER2+) metastatic breast cancer (MBC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.1102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
13
|
Lee S, Park Y, Sun J, Seo J, Lee J, Nam S, Yang J, Ahn J, Im Y. Individualized surveillance and follow-up based on breast cancer (BC) subtypes and risk of relapse in BC patients who received curative surgery. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e11053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
14
|
Park Y, Lee S, Kong J, Cho E, Choi Y, Lee J, Nam S, Yang J, Ahn J, Im Y. Clinical relevance of TNM staging system according to breast cancer (BC) subtypes. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.632] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
15
|
Ahn J, Jung K, Kim S, Lee K, Ro J, Park Y, Ahn J, Im Y, Im S, Lee M, Kim S. Zoledronic Acid Prevents Bone Loss in Premenopausal Women with Early Breast Cancer Undergoing Adjuvant Chemotherapy: A Phase III Study of Korean Cancer Study Group (KCSG-BR06-01). Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-2104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Adjuvant chemotherapy results in early menopause in the majority of premenopausal patients due to premature ovarian failure and consequent skeletal morbidity. Zoledronic acid (ZA) is known to prevent bone loss in postmenopausal women. The purpose of this study was to determine whether ZA can prevent bone loss in premenopausal women undergoing adjuvant chemotherapy for breast cancer.Methods: This study is a randomized, open-label, phase III multicenter trial. Premenopausal women older than age 40 were randomly assigned to ZA group (two infusions of 4 mg IV, every 6 months) or observation group after surgery. All patients were treated with the same adjuvant chemotherapy regimen (AC-->T; 4 cycles of AC followed by 4 cycles of paclitaxel or docetaxel). The first infusion of ZA was given on day 1 of the first chemotherapy. All patients received supplementations with oral calcium 600 mg/d and vitamin D 400 IU/d. The bone mineral density (BMD) was measured at the baseline, 6th and 12th months. Bone turnover markers were measured before chemotherapy and in 3, 6, 12 months.Results: Between March 2007 and May 2008, a total of 110 premenopausal women were enrolled in this study and the majority of women (91.8%) developed amenorrhea at 1 year post chemotherapy. The mean percent change of BMD in lumbar spine was +0.5% in the ZA group versus -3.6% in the observation group at 6 months (p<0.01) and, -1.0% versus -7.5%, at 12 months (p<0.01). Differences in percent change of BMD from baseline between two groups were 6.5% (95% CI, 5.2 to 7.9%) for the lumbar spine, and 3.6% (95% CI, 2.2% to 5.1%) for the femoral neck (p<0.01). Type I collagen metabolite PINP levels at 12 months were significantly higher in the observation group than in the ZA group; 72.7 mg/l (range 21.8∼250 mg/l) versus 30.8 mg/l (range 14.7∼62.7 mg/l) (p=0.0001). Changes of other bone turnover markers including urinary N-telopeptide, bone alkaline phosphatase, and serum C-telopeptide were also significantly different between two groups (p<0.01). ZA was generally well tolerated, and adverse event profile was similar between two groups.Conclusion: Adjuvant chemotherapy with AC-->T induced amenorrhea in the majority of patients over 40 years in this study. Treatment with two infusions of ZA 4 mg every 6 months effectively prevented bone loss within the first year of adjuvant chemotherapy for early breast cancer in premenopausal women. Regular BMD measurements and early bisphosphonate therapy should be considered for this population.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 2104.
Collapse
Affiliation(s)
- J. Ahn
- 1Asan Medical Center, Republic of Korea
| | - K. Jung
- 1Asan Medical Center, Republic of Korea
| | - S. Kim
- 1Asan Medical Center, Republic of Korea
| | - K. Lee
- 2National Cancer Center, Republic of Korea
| | - J. Ro
- 2National Cancer Center, Republic of Korea
| | - Y. Park
- 3Samgsung Medical Center, Republic of Korea
| | - J. Ahn
- 3Samgsung Medical Center, Republic of Korea
| | - Y. Im
- 3Samgsung Medical Center, Republic of Korea
| | - S. Im
- 4Seoul National University Hospital, Republic of Korea
| | - M. Lee
- 5Inha University Hospital, Republic of Korea
| | - S. Kim
- 6Kyunghee University Hospital, Republic of Korea
| |
Collapse
|
16
|
Kim S, Lee J, Park Y, Park J, Ahn J, Im Y, Kang W, Park K, Ahn M. 9138 Prognostic model to predict outcomes in non-small cell lung cancer patients treated with erlotinib as a salvage treatment. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71851-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
17
|
Park Y, Kim S, Ok O, Baek H, Lee J, Nam S, Yang J, Cho E, Ahn J, Im Y. Risk stratification by hormonal receptor (ER, PgR) and HER2 status in small (≤1cm) invasive breast cancer: Who might be a possible candidate for adjuvant treatment? J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.564] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
564 Background: With the increasing use of screening mammography, the proportion of ≤ 1 cm invasive breast cancer is increasing. Identification of breast cancer molecular subtypes has resulted in a better appreciation of the biologic heterogeneity, which is not fully explained by clinicopathologic features including staging system. The aims of this study were: 1) to identify the risk factors of systemic metastases in patients with ≤ 1 cm invasive breast cancer and 2) to investigate the patients group at greatest risk of such failure even in these small tumors. Method: Data were collected retrospectively in the breast cancer registry of our institution for patients with invasive breast cancer from October 1994 to December 2004. Results: Of 4,036 patients who received curative breast cancer surgery, 466 patients who had T1a or T1b breast cancer were identified. 39 patients who received neoadjuvant chemotherapy were excluded in this study. Ipsilateral axillary lymph node involvement was found in 13% (57/427) at the time of surgery. Axillary lymph node involvement was much more common in HER-2 positive group (33% vs 11%, p < 0.0001) and triple negative (TN) group (24% vs 11%, p = 0.002) than in hormone receptor positive group. During median 61 months of follow-up, overall 10 year estimated distant relapse-free survival (DRFS) and overall survival (OS) were 95% and 92%, respectively. Multivariate analysis was conducted in 370 (T1aN0, T1bN0) patients, who had no lymph node involvement. In Cox-regression model, HER-2 positivity and triple negativity were identified as independent prognostic factors to predict DRFS [Hazard ratio (HR) 8.8, p = 0.003 for HER-2 positive group; HR 5.1, p = 0.026 for TN group] and OS (HR 5.0, p = 0.067 for HER-2 positive group; HR 11.1, p = 0.017 for TN group) in T1bN0 tumors. Limiting to T1aN0 tumors, statistical significance was not maintained. Conclusions: Even though T1aN0 and T1bN0 tumors have been known to have a relative low risk of systemic failure, anti-HER-2 directed therapy for HER-2 positive group and new innovative adjuvant systemic treatment for TN group in patients with T1bN0 tumor should be considered. Prospective adjuvant trials should be warranted in these subgroups of patients. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- Y. Park
- Samsung Medical Center, Seoul, Republic of Korea
| | - S. Kim
- Samsung Medical Center, Seoul, Republic of Korea
| | - O. Ok
- Samsung Medical Center, Seoul, Republic of Korea
| | - H. Baek
- Samsung Medical Center, Seoul, Republic of Korea
| | - J. Lee
- Samsung Medical Center, Seoul, Republic of Korea
| | - S. Nam
- Samsung Medical Center, Seoul, Republic of Korea
| | - J. Yang
- Samsung Medical Center, Seoul, Republic of Korea
| | - E. Cho
- Samsung Medical Center, Seoul, Republic of Korea
| | - J. Ahn
- Samsung Medical Center, Seoul, Republic of Korea
| | - Y. Im
- Samsung Medical Center, Seoul, Republic of Korea
| |
Collapse
|
18
|
Choi J, Kim K, Kim W, Lee S, Lim H, Cho E, Han B, Kim Y, Ahn J, Im Y, Lee J, Nam S, Yang J. Evaluation of response to neoadjuvant chemotherapy in primary breast cancer using PET. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-4019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #4019
Purpose
 To estimate the usefulness of PET scan to assess the response of neoadjuvant chemotherapy, PET scan results were compared with conventional imaging modalities(US and MRI).
 Patients and Methods
 Fourty-one patients undergoing neoadjuvant chemotherapy between December 2004 and March 2008 were included. PET scan was performed before and after chemotherapy. Pathologic results were classified into two groups; pathological complete response(pCR) and non-pCR. Clinical responses were assessed with the results of imaging modalities such as post-chemotherapy size or pSUV(postTx), size difference between treatment(delta) and reduction rate(RR) of size or pSUV, and they are compared with postoperative pathologic results.
 Results
 7 out of 41 patients (17.1%) had pCR. The results of US shows that postTx size (1.7±1.5cm) of pCR was not dfferent from those of non-pCR (3.6±3.0cm), and the delta (3.1±1.9cm) and RR (67.7±29.1%) of pCR were higher than those of non-pCR (1.3±1.3cm, 31.0±25.4%), respectively. As a result of MRI, postTx size, delta, RR of pCR was differ from those of non-pCR (1.0±1.7cm vs 2.8±1.7cm p<0.05; 4.5±1.0cm vs 2.3±1.8cm, p<0.05; 88.0±20.8% vs 44.6±24.7%, p<0.01). In PET scan, only postTx pSUV of pCR was differ from that of non-pCR (1.4±1.3 vs 5.3±8.3cm, p<0.05). As a result of receiver operating characteristic curve analyses for the prediction of pathological response of breast cancer, area under curve values (95% confidence interval) of US, MRI, PET for delta were 0.83(0.69∼0.98), 0.91(0.80∼1.01), 0.62(0.38∼0.86), and those of RR were 0.80(0.60∼0.99), 0.90(0.77∼1.02), 0.72(0.47∼0.96), respectively
 Conclusions
 We suggest that MRI is useful method to evaluate the response of neoadjuvant chemotherapy. Although PET scan shows less effective for evaluating the response of chemotherapy than MRI, PET scan with the ability to detect the distant metastatic lesions may be helpful to decide the proper management plans for advanced breast cancer.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 4019.
Collapse
Affiliation(s)
- J Choi
- 1 Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - K Kim
- 1 Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - W Kim
- 1 Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - S Lee
- 1 Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - H Lim
- 1 Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - E Cho
- 2 Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - B Han
- 3 Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine
| | - Y Kim
- 4 Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - J Ahn
- 5 Medical Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - Y Im
- 5 Medical Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - J Lee
- 1 Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - S Nam
- 1 Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - J Yang
- 1 Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| |
Collapse
|
19
|
Yi S, Uhm J, Cho E, Lee S, Park M, Jun H, Park Y, Ahn J, Im Y, Kang W, Park K. Clinical outcomes of metastatic breast cancer patients with triple-negative phenotype who received platinum-containing chemotherapy. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.1008] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
20
|
Im Y, Lee J, Cho E, Kim H, Ahn J, Park Y, Nam S, Kang W, Park K, Yang J. P53 Evaluation of ER, and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer. Breast 2007. [DOI: 10.1016/s0960-9776(07)70118-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
21
|
Abstract
15533 Background: Anaplastic thyroid cancer (ATC) is a rare but highly aggressive neoplasm with a dismal prognosis. However, a few patients survive for a long time after treatment. We tried to identify prognostic factors of this disease and analyzed treatment outcomes in patients with ATC. Methods: We reviewed the medical records of 15 patients diagnosed with ATC in our institution between 1988 and 2003. The survival was compared by the Kaplan-Meier log-rank test. Results: The female-to-male ratio was 1.5:1 (9 women and 6 men), and the mean age at diagnosis was 63.9 years (range, 44–91). The mean tumor size was 6.3cm (range, 4–10 cm). Extrathyroidal invasion was present in 12 cases and distant metastasis at diagnosis was present in 6 cases. Surgery was performed in 8 cases. Radiotherapy was used for 10 cases and chemotherapy for 5 cases. The mean overall survival time of the 15 patients was 237 days (range, 28–717 days). The 6-, 12-, 18- and 24-month survival rates were 33%, 26%, 13% and 0%. No association was found between survival and presenting symptoms, age, gender, tumor size, previous goiter history, extrathyroidal invasion, distant metastasis, surgery, radiotherapy or chemotherapy. A significantly better outcome was observed in patients received triple modality treatment (surgery, radiotherapy and chemotherapy) than in those received single or dual modality treatment (P = 0.05). Conclusions: Although most patients with ATC had a poor prognosis, a multimodal approach including surgery, radiotherapy and chemotherapy, might improve survival. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- Y. Lee
- Kyungpook National University Hospital, Daegu, Republic of Korea
| | - J. Jung
- Kyungpook National University Hospital, Daegu, Republic of Korea
| | - G. Hwang
- Kyungpook National University Hospital, Daegu, Republic of Korea
| | - H. Park
- Kyungpook National University Hospital, Daegu, Republic of Korea
| | - Y. Im
- Kyungpook National University Hospital, Daegu, Republic of Korea
| |
Collapse
|
22
|
Abstract
STUDY OBJECTIVE To determine the relative bioavailability of lamotrigine (LTG) chewable dispersible tablets after rectal administration. DESIGN Two-period, crossover study with a 2-week washout between dosing periods. SETTING Clinical research center. PATIENTS Twelve healthy adult volunteers. INTERVENTION One hundred milligrams of a LTG chewable dispersible tablet was administered by oral and rectal routes. MEASUREMENTS AND MAIN RESULTS Plasma samples were collected before and up to 120 hours after drug administration. The samples were analyzed for LTG by high-performance liquid chromatography, and the relative bioavailability was determined. Drug concentrations were lower after rectal than after oral administration. The relative bioavailability (F = AUC(rectal)/AUC(oral)) was 0.52 +/- 0.23 (SD). CONCLUSION Drug prepared from LTG chewable dispersible tablets is absorbed rectally, although not to the same extent as when given orally. Rectal administration of suspension of these tablets can be an acceptable route of administration.
Collapse
Affiliation(s)
- A K Birnbaum
- Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis 55455, USA
| | | | | | | |
Collapse
|